---
title: "KRAS突变型癌症的多组学综合表征"
date: 2023-02-04T08:03:24Z
draft: ["false"]
tags: [
  "fetched",
  "医学僧的科研日记"
]
categories: ["Acdemic"]
---
KRAS突变型癌症的多组学综合表征 by 医学僧的科研日记
------
<div><p><span>今天和大家分享一篇于<span lang="EN-US">2022</span>年<span lang="EN-US">8</span>月在</span><strong><em><span lang="EN-US">Theranostics</span></em></strong><span>上发表的文章<span lang="EN-US">"</span></span><em><span lang="EN-US">Integrated multi-omicscharacterization of KRAS mutant colorectal cancer</span></em><span lang="EN-US">"</span><span>。<span lang="EN-US">KRAS</span>突变是结直肠癌（<span lang="EN-US">CRC</span>）中最常见的致癌异常。<span lang="EN-US">CRC</span>中<span lang="EN-US">KRAS</span>突变的分子机制和临床意义尚不清楚，并在这些肿瘤中表现出高度异质性。本文利用<span lang="EN-US">KRAS</span>突变<span lang="EN-US">CRC</span>肿瘤的多组学数据（基因组、转录组学、蛋白质组学和磷酸蛋白质组学等），阐明了<span lang="EN-US">KRAS</span>突变<span lang="EN-US">CRC</span>的分子异质性，并揭示了这些肿瘤的新的生物学亚型和治疗可能性。具体怎么实现的，一起来学习一下吧。</span><span></span></p><section><iframe data-vidtype="2" data-mpvid="wxv_2777737995268440067" data-cover="http%3A%2F%2Fmmbiz.qpic.cn%2Fmmbiz_jpg%2FeBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RvibJWYtjB2KMUmwsv7fy9vJ3oz63H7CmFgTYPWxTvTyyXymia20fLndw%2F0%3Fwx_fmt%3Djpeg" allowfullscreen="" frameborder="0" data-ratio="2" data-w="2160" data-src="https://mp.weixin.qq.com/mp/readtemplate?t=pages/video_player_tmpl&amp;action=mpvideo&amp;auto=0&amp;vid=wxv_2777737995268440067"></iframe></section><h3><span>一、研究背景</span></h3><section><span></span></section><p><span lang="EN-US">1.KRAS</span><span>是结直肠癌症最常见的突变致癌基因之一，一旦<span lang="EN-US">KRAS</span>突变发生，<span lang="EN-US">GTP</span>的水解被破坏或核苷酸交换被增强，导致<span lang="EN-US">KRAS</span>在活性状态下积聚，启动下游信号通路，从而促进肿瘤发展及免疫逃逸</span></p><p><span lang="EN-US">2.KRAS</span><span>突变型肿瘤存在异质性，不同<span lang="EN-US">KRAS</span>突变对下游激活信号不同，且针对不同突变型的药物临床疗效也不同，需要进一步探索生物学亚型和分子靶点，以指导<span lang="EN-US">KRAS</span>突变<span lang="EN-US">CRC</span>患者的预后和治疗</span></p><p><span lang="EN-US">3.</span><span>鉴于磷酸化级联主导<span lang="EN-US">KRAS</span>诱导的下游信号传导，获得蛋白质组和磷酸蛋白质组的全面概况将有助于提高对<span lang="EN-US">KRAS</span>突变癌症表型异质性的理解</span></p><p><span lang="EN-US">4.KRAS</span><span>突变破坏固有的<span lang="EN-US">GTP-GDP</span>循环允许突变<span lang="EN-US">KRAS</span>蛋白以活性状态积累，从而组成性激活下游<span lang="EN-US">MAPK</span>和<span lang="EN-US">PI3K</span>信号级联，从而导致细胞增殖和存活(<strong>下</strong><strong>图示</strong>)</span></p><p><span><img data-ratio="0.6369942196531792" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Rv60NXZP8Vooo0zibiadoS0qR4MpFQQFuHrY7bmdDObtVo3ibicTOGblbwg/640?wx_fmt=png" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Rv60NXZP8Vooo0zibiadoS0qR4MpFQQFuHrY7bmdDObtVo3ibicTOGblbwg/640?wx_fmt=png"></span></p><section><span></span></section><h3><span>二、研究队列</span></h3><p><span lang="EN-US">1.CPTAC </span><span>临床蛋白质组肿瘤分析联盟</span></p><p><span lang="EN-US">2.TCGA-COAD/READ</span></p><p><span lang="EN-US">3.CCRC </span><span>中国结直肠癌队列</span></p><p><span lang="EN-US">4.MSK</span><span>队列<span lang="EN-US"> KRAS</span>突变队列</span></p><p><span lang="EN-US">5.GSE39582</span><span>、<span lang="EN-US">GSE87211</span></span><span></span></p><h3><span>三、结果简述</span></h3><section><span></span><span><span><span></span></span></span></section><p><strong><span lang="EN-US">1</span><span>、<span lang="EN-US">KRAS</span>突变与野生型结直肠癌的分子景观：</span></strong><span lang="EN-US">在TCGA</span><span>和<span lang="EN-US">CPTAC</span>数据集中，最常见的<span lang="EN-US">KRAS</span>突变是<span lang="EN-US">KRAS-G12D/V/S/C</span>，其次是<span lang="EN-US">G13D/C</span>（<strong>图<span lang="EN-US">1A</span></strong>）。<span lang="EN-US">Kaplan-Meier</span>分析表明<span lang="EN-US">KRAS</span>突变组的预后更差（<strong>图<span lang="EN-US">1B</span></strong>），调整年龄、性别、临床阶段和<span lang="EN-US">MSI</span>状态后，多变量回归模型中的相关性仍然显著（<strong>图<span lang="EN-US">1C</span></strong>）。基于转录组表达谱进行了基因集富集分析突变组在致癌信号通路中表现出更高的富集，如肿瘤中的上皮间质转化和<span lang="EN-US">Wnt</span>信号。野生型主要在趋化因子受体结合趋化因子的基因集、淋巴和非淋巴细胞之间的免疫调节相互作用、<span lang="EN-US">PD-1</span>信号等方面表现出富集，表明更强的免疫激活。此外作者利用蛋白质组学数据来识别差异调节的蛋白质和过度表达的途径。肿瘤恶性表型相关的<span lang="EN-US">IGFBP2</span>和<span lang="EN-US">KRT18</span>在<span lang="EN-US">KRASMut</span>亚型中显著富集，而中性粒细胞和巨噬细胞相关的<span lang="EN-US">CD177</span>、<span lang="EN-US">MMP1</span>和<span lang="EN-US">ARG1</span>在<span lang="EN-US">WT</span>亚型中富集（<strong>图1<span lang="EN-US">E-F</span></strong>）。随后整理了<span lang="EN-US">CPTAC</span>队列中的转录组学、蛋白质组学和磷酸蛋白质组学数据，并比较了<span lang="EN-US">KRAS-Mut</span>和<span lang="EN-US">KRAS-WT</span>肿瘤中的差异调节。<span lang="EN-US">KRAS Mut</span>肿瘤显示出肿瘤迁移（<span lang="EN-US">TGFBR2-S553</span>和<span lang="EN-US">EPHB3</span>）和<span lang="EN-US">PI3K/AKT</span>激活（<span lang="EN-US">PIP4K2C</span>和<span lang="EN-US">PIK3R1</span>）的显著上调，而<span lang="EN-US">KRAS-WT</span>组在免疫调节（<span lang="EN-US">TAP1/2</span>、<span lang="EN-US">IFITM1</span>和<span lang="EN-US">IFIH1-S301</span>）和细胞代谢（<span lang="EN-US">DGAT1</span>和<span lang="EN-US">HINT3</span>）方面富集。</span></p><p><img data-backh="128" data-backw="287" data-ratio="0.44619799139167865" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Ru9nn1uG42mLNhuapgjOSZMTQuia4kLswA8Efj4AKHg8S3NicwknHKWKw/640?wx_fmt=png" data-type="png" data-w="697" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Ru9nn1uG42mLNhuapgjOSZMTQuia4kLswA8Efj4AKHg8S3NicwknHKWKw/640?wx_fmt=png"></p><p><span> <img data-backh="129" data-backw="274" data-ratio="0.47203274215552526" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RDTHygcf1jaC62Gd7O3Vv1qWCic6icNvyC7zKmmJemTvDHXZjtFqQFibow/640?wx_fmt=png" data-type="png" data-w="733" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RDTHygcf1jaC62Gd7O3Vv1qWCic6icNvyC7zKmmJemTvDHXZjtFqQFibow/640?wx_fmt=png"></span></p><p><img data-backh="163" data-backw="183" data-galleryid="" data-ratio="0.8885424785658612" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RbGgUb3JGIWIhRoLuCcYOFExzsOibibSkF7nd1wPUTNPLRsNw5ETR7gKg/640?wx_fmt=png" data-type="png" data-w="1283" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RbGgUb3JGIWIhRoLuCcYOFExzsOibibSkF7nd1wPUTNPLRsNw5ETR7gKg/640?wx_fmt=png"><span>  </span><span></span><img data-backh="171" data-backw="384" data-galleryid="" data-ratio="0.4450704225352113" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0ReSicIqvMY4yicj7CM6DMN2FotKDoa1VJOyGicerqI3nStWzvCyibsKSGsw/640?wx_fmt=png" data-type="png" data-w="2485" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0ReSicIqvMY4yicj7CM6DMN2FotKDoa1VJOyGicerqI3nStWzvCyibsKSGsw/640?wx_fmt=png"><span>图1.</span><span>KRAS突变与野生型结直肠癌的分子景观</span></p><p><span>越来越多的证据集中在与肿瘤发生和免疫逃避有关的基因组突变上，这些突变在癌症演变过程中具有选择性优势。因此作者比较了<span lang="EN-US">KRAS-Mut</span>和<span lang="EN-US">KRAS-WT</span>中的肿瘤突变负荷，并观察到<span lang="EN-US">TCGA</span>和<span lang="EN-US">CPTAC</span>队列中没有差异。接受免疫检查点抑制剂的大多数类型肿瘤的免疫应答率在<span lang="EN-US">KRAS Mut</span>组和<span lang="EN-US">-WT</span>组之间没有显著差异（<strong>图<span lang="EN-US">S1A-B</span></strong>）。进一步比较了<span lang="EN-US">KRAS-Mut</span>和<span lang="EN-US">KRAS-WT</span>样本中的体细胞拷贝数改变（<span lang="EN-US">SCNA</span>）和非整倍体分数。在染色体水平上，<span lang="EN-US">KRAS Mut</span>肿瘤显示出比<span lang="EN-US">WT</span>肿瘤更低程度的臂水平<span lang="EN-US">SCNA</span>，并且改变主要集中在<span lang="EN-US">chr5q</span>、<span lang="EN-US">chr9q</span>和<span lang="EN-US">chr12</span>（<strong>图S<span lang="EN-US">1C</span></strong>）。此外，作者还观察到<span lang="EN-US">KRAS Mut</span>与<span lang="EN-US">WT</span>肿瘤的非整倍体分数（肿瘤中臂水平增加和减少的总数）显著降低（<strong>图S<span lang="EN-US">1D</span></strong>）。使用体细胞相互作用函数，我们进行了成对<span lang="EN-US">Fisher</span>精确测试，以检测<span lang="EN-US">KRAS</span>突变与<span lang="EN-US">CRC</span>中<span lang="EN-US">25</span>个最常见突变基因之间的关系（<strong>图S<span lang="EN-US">1E</span></strong>）。<span lang="EN-US">ARID1A</span>和<span lang="EN-US">ACVR2A</span>突变与肿瘤中的<span lang="EN-US">KRAS</span>突变互斥，进一步表明<span lang="EN-US">CRC</span>中的遗传异常。</span></p><p><img data-galleryid="" data-ratio="0.3879573170731707" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RynUO95IayaabB2yL1TvnBT1oC5jluC8gMUNfGTdoiaGpmbuqaMFZ1yw/640?wx_fmt=png" data-type="png" data-w="2624" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RynUO95IayaabB2yL1TvnBT1oC5jluC8gMUNfGTdoiaGpmbuqaMFZ1yw/640?wx_fmt=png"></p><p><img data-galleryid="" data-ratio="0.4664228723404255" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R4dUHicBc3HzraKicXiazgibf6VvAFT2thtPfBhcTKQNqMuwrbKiaE48bwCA/640?wx_fmt=png" data-type="png" data-w="3008" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R4dUHicBc3HzraKicXiazgibf6VvAFT2thtPfBhcTKQNqMuwrbKiaE48bwCA/640?wx_fmt=png"></p><p><img data-backh="496" data-backw="578" data-galleryid="" data-ratio="0.858359133126935" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R0qfFDOR1HgWmrP1mZxBjfs7b3R90BXLhZicBtiaNbaicRe9vApNWPHRIA/640?wx_fmt=png" data-type="png" data-w="1292" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R0qfFDOR1HgWmrP1mZxBjfs7b3R90BXLhZicBtiaNbaicRe9vApNWPHRIA/640?wx_fmt=png"></p><p><span><span><span>图S1.</span><span>KRAS突变与野生型结直肠癌的基因组特征</span></span></span><strong></strong></p><p><strong><span lang="EN-US">2. KRAS </span><span>突变型结直肠癌的单细胞转录组概况</span><strong><span>：</span></strong></strong><span>首</span><span>先为了研究</span><span lang="EN-US">TME</span><span>在肿瘤进展和免疫逃逸中起着作用及对免疫疗法的反应产生影响，作者量化基质细胞和免疫细胞浸润，并研究</span><span lang="EN-US">CRC</span><span>中细胞亚群的变化。</span><span>大多数细胞亚群在</span><span lang="EN-US">KRAS-Mut</span><span>和</span><span lang="EN-US">KRAS-WT</span><span>肿瘤之间存在显著差异。</span><span lang="EN-US">KRAS</span><span>突变的肿瘤以上皮细胞和</span><span lang="EN-US">Treg</span><span>细胞的增加为特征，而</span><span lang="EN-US">KRAS-WT</span><span>肿瘤以</span><span lang="EN-US">CD4+T</span><span>细胞、巨噬细胞、</span><span lang="EN-US">pDC</span><span>等为特征（</span><strong><span>图</span><span lang="EN-US">2A</span></strong><span>）。</span><span>为了更准确地描绘</span><span lang="EN-US">KRAS Mut CRC</span><span>的细胞亚群景观，作者从</span><span lang="EN-US">SMC</span><span>和</span><span lang="EN-US">KUL</span><span>数据集收集并整理了</span><span lang="EN-US">10</span><span>×</span><span lang="EN-US">ScRNA-seq</span><span>转录组数据，最后，获得了来自</span><span lang="EN-US">16</span><span>个</span><span lang="EN-US">KRAS-WT</span><span>和</span><span lang="EN-US">13</span><span>个</span><span lang="EN-US">KRAS-Mut</span><span>结直肠癌的总共</span><span lang="EN-US">55539</span><span>个单细胞，并通过</span><span lang="EN-US">Seurat 4.0</span><span>进行了分析（</span><strong><span>图</span><span lang="EN-US">2B</span><span>，左图</span></strong><span>），将</span><span lang="EN-US">CRC</span><span>单元聚类为</span><span lang="EN-US">29</span><span>个具有差异表达特征的聚类，</span><span>最终确定了六种主要细胞类型，即淋巴细胞</span><span lang="EN-US">/</span><span>浆细胞、上皮细胞、成纤维细胞</span><span lang="EN-US">/</span><span>内皮细胞、髓细胞、</span><span lang="EN-US">T/</span><span>自然杀伤细胞（</span><span lang="EN-US">NK</span><span>）</span><span lang="EN-US">/NK T</span><span>淋巴细胞和肥大细胞（图</span><span lang="EN-US">2B</span><span>，右图）。</span><span>作者发现</span><span lang="EN-US">T</span><span>细胞、</span><span lang="EN-US">B</span><span>细胞、髓细胞和基质细胞在</span><span lang="EN-US">KRAS-Mut</span><span>和</span><span lang="EN-US">KRAS-WT</span><span>肿瘤中的分布显著不同（</span><strong><span>图</span><span lang="EN-US">2B</span><span>，右图</span></strong><span>）。</span><span>因此，作者提取了四种主要的细胞类型，并将它们进一步细分为特定的细胞亚群。</span><span>采用了上述相同的工作流程，将</span><span lang="EN-US">T</span><span>细胞、</span><span lang="EN-US">B</span><span>细胞、髓细胞和基质细胞分别分为八个、五个、八个和十一个亚群（</span><strong><span>图</span><span lang="EN-US">2C</span></strong><span>）。</span><span>比较分析表明，</span><span lang="EN-US">KRAS-WT</span><span>肿瘤中</span><span lang="EN-US">CD4+T</span><span>细胞、</span><span lang="EN-US">CD8+T</span><span>细胞和调节性</span><span lang="EN-US">T</span><span>细胞的细胞亚群分布显著升高，而</span><span lang="EN-US">KRAS-mut</span><span>肿瘤中</span><span lang="EN-US">IgG+</span><span>浆细胞（</span><span lang="EN-US">B</span><span>细胞）、</span><span lang="EN-US">SPP1+</span><span>巨噬细胞（髓细胞）和肌成纤维细胞（基质细胞）显著增加（</span><strong><span>图</span><span lang="EN-US">2C-2D</span></strong><span>）。</span></p><p><img data-backh="520" data-backw="578" data-galleryid="" data-ratio="0.898989898989899" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RvJSAVXCnlA4WnnhTSwHMibibQ1zGEmsib2bw4AADU1LslzjjGKj6nQpQA/640?wx_fmt=png" data-type="png" data-w="1089" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RvJSAVXCnlA4WnnhTSwHMibibQ1zGEmsib2bw4AADU1LslzjjGKj6nQpQA/640?wx_fmt=png"></p><p><span>图2.KRAS-Mut结直肠癌的单细胞转录组景观</span></p><p><span><strong>3.<strong><span><span>鉴定<span lang="EN-US">KRAS Mut</span>亚群的分子亚型：</span></span></strong></strong></span><span>作者进一步整合了</span><span lang="EN-US">CPTAC</span><span>数据集中公开的转录组学、蛋白质组学和磷酸蛋白质组学数据，以研究</span><span lang="EN-US">KRAS Mut</span><span>肿瘤的共同分子亚型和治疗脆弱性（</span><strong><span>图</span><span lang="EN-US">3A</span></strong><span>）。使用相似网络融合（</span><span lang="EN-US">SNF</span><span>）方法基于三种组学数据进行了无监督聚类，并将</span><span lang="EN-US">KRAS</span><span>突变</span><span lang="EN-US">CRC</span><span>分类为两个稳健子集（</span><strong><span>图</span><span lang="EN-US">3B</span></strong><span>）。此外无监督聚类也应用于组学数据的每个单独层，并显示仅来自转录组、蛋白质组或磷酸蛋白质组的子集的平均剪影宽度小于来自整合多组学的子集的剪影宽度（</span><strong><span>图</span><span lang="EN-US">3C</span><span>、图</span><span lang="EN-US">S3C</span></strong><span>），这表明整合三种组学数据可以更准确地对</span><span lang="EN-US">KRAS Mut</span><span>结直肠癌进行分类。为了识别</span><span lang="EN-US">KM1</span><span>和</span><span lang="EN-US">KM2</span><span>亚型之间最具区别性的分子特征，作者使用随机森林学习模型提取了最重要的分子特征以区分亚型。该分析确定了</span><span lang="EN-US">5</span><span>种</span><span lang="EN-US">mRNA</span><span>、</span><span lang="EN-US">10</span><span>种蛋白质和</span><span lang="EN-US">19</span><span>种磷蛋白分别作为</span><span lang="EN-US">mRNA</span><span>、蛋白质和磷蛋白水平的亚型特征（</span><strong><span>图</span><span lang="EN-US">3D</span><span>、图</span><span lang="EN-US">S3D</span></strong><span>）。作者进一步比较了</span><span lang="EN-US">CPTAC</span><span>和</span><span lang="EN-US">TCGA</span><span>中</span><span lang="EN-US">KM1</span><span>和</span><span lang="EN-US">KM2</span><span>亚型之间</span><span lang="EN-US">KRAS</span><span>（</span><span lang="EN-US">G12D/V/C</span><span>、</span><span lang="EN-US">G13D</span><span>等）中的突变残基，发现两种亚型之间没有统计学显著差异（</span><strong><span>图</span><span lang="EN-US">3E-3F</span></strong><span>）。为了探讨亚型特征的潜在临床应用，比较了两个分子亚群之间的预后。</span><span lang="EN-US">CPTAC</span><span>队列中的</span><span lang="EN-US">KM1</span><span>亚型与更好的预后相关，与</span><span lang="EN-US">KM2</span><span>亚型相比，没有死亡结局，尽管考虑到样本量小，生存分析没有统计学意义（</span><strong><span>图</span><span lang="EN-US">3G</span></strong><span>）。作者还比较了独立队列中基于</span><span lang="EN-US">KRAS</span><span>分子亚型的预后，并确定</span><span lang="EN-US">KM1</span><span>亚型与</span><span lang="EN-US">TCGA</span><span>、</span><span lang="EN-US">CIT</span><span>、</span><span lang="EN-US">GSE87211</span><span>和</span><span lang="EN-US">CCRC</span><span>队列中更好的生存率显著相关（</span><strong><span>图</span><span lang="EN-US">3H</span></strong><span>）。</span></p><p><img data-backh="554" data-backw="578" data-galleryid="" data-ratio="0.9573690621193667" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R64WuRsqtxaiaCbMZA8Qb8kXmFv8YAmDQ47tiavX8TXX5B1QtzIA42WTQ/640?wx_fmt=png" data-type="png" data-w="821" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0R64WuRsqtxaiaCbMZA8Qb8kXmFv8YAmDQ47tiavX8TXX5B1QtzIA42WTQ/640?wx_fmt=png"></p><p><span>图3.识别KRAS-Mut亚群的分子亚型确定癌症患者的基因组和预后特征。</span></p><section><strong><span><span>4.</span></span><span lang="EN-US">KRAS Mut</span><span>结直肠癌的肿瘤基因组变异</span><strong><span><span>：</span></span></strong></strong><strong><span><strong><span></span></strong></span></strong><span></span></section><p><span>为了进一步了解<span lang="EN-US">KRAS</span>突变结直肠癌患者的基因组景观，作者在<span lang="EN-US">CPTAC</span>和<span lang="EN-US">TCGA</span>队列中进行了<span lang="EN-US">SMG</span>分析，并比较了<span lang="EN-US">KM1</span>、<span lang="EN-US">KM2</span>和<span lang="EN-US">KRAS-WT</span>亚群中的基因突变频率。<span lang="EN-US">TCGA</span>和<span lang="EN-US">CPTAC</span>队列中的突变谱显示，<span lang="EN-US">ARID1A</span>和<span lang="EN-US">BRAF</span>在<span lang="EN-US">KRAS-WT</span>亚组中的突变率高于<span lang="EN-US">KRAS-Mut</span>亚组（<strong>图<span lang="EN-US">4A</span></strong>）。然后，作者分析了<span lang="EN-US">CRC</span>肿瘤中<span lang="EN-US">KM1</span>、<span lang="EN-US">KM2</span>和<span lang="EN-US">KRAS-WT</span>亚型中在三核苷酸背景下发生的<span lang="EN-US">96</span>个可能突变的基质中的单核苷酸变体（<span lang="EN-US">SNV</span>）（<strong>图<span lang="EN-US">4B</span></strong>）。饼图显示，与<span lang="EN-US">KRAS-WT</span>肿瘤相比，<span lang="EN-US">KM1</span>和<span lang="EN-US">KM2</span>肿瘤的<span lang="EN-US">C</span>＞<span lang="EN-US">A</span>转变略有增加（<strong>图<span lang="EN-US">4B</span>，顶部</strong>）。<span lang="EN-US">Lego</span>图显示<span lang="EN-US">CRC</span>中的主要突变是<span lang="EN-US">ApCpN</span>三核苷酸位点的<span lang="EN-US">C&gt;T</span>转变，而<span lang="EN-US">GpCpG</span>位点的<span lang="EN-US">C&gt;A</span>转变在<span lang="EN-US">KM2</span>亚型中特别突出（<strong>图<span lang="EN-US">4B</span>，底部</strong>），表明<span lang="EN-US">KRAS</span>突变异质性中的特定突变过程起作用。随后，作者从基因组数据中提取了五个突变特征（<strong>图<span lang="EN-US">4C</span></strong>），包括<span lang="EN-US">DNA</span>错配修复相关特征（<span lang="EN-US">SBS15</span>和<span lang="EN-US">SBS44</span>）的缺陷、<span lang="EN-US">5-</span>甲基胞嘧啶的自发或酶脱氨基（<span lang="EN-US">SBS1</span>）和聚合酶<span lang="EN-US">ε</span>外切酶结构域突变（<span lang="EN-US">SBS10b</span>）（<strong>图<span lang="EN-US">4C</span></strong>）。<span lang="EN-US">SBS44</span>标记导致的突变计数显示<span lang="EN-US">KRAS-WT</span>肿瘤显著增加，而<span lang="EN-US">SBS15</span>标记显示<span lang="EN-US">KM1</span>亚型显著减少（<strong>图<span lang="EN-US">4D</span></strong>）。臂级<span lang="EN-US">SCNA</span>结果表明，<span lang="EN-US">chr2</span>、<span lang="EN-US">chr5p</span>、<span lang="EN-US">chr7q</span>、<span lang="EN-US">chr8p</span>、<span lang="EN-US">chr12</span>和<span lang="EN-US">chr16</span>中的细胞带包含最频繁扩增或缺失的区域（<strong>图<span lang="EN-US">S5D</span></strong>）。局灶性<span lang="EN-US">SCNA</span>显示<span lang="EN-US">KM1</span>亚型中<span lang="EN-US">2q31.2</span>、<span lang="EN-US">5p15.33</span>、<span lang="EN-US">7q36.3</span>和<span lang="EN-US">KM2</span>亚型中<span lang="EN-US">12p13.33</span>的细胞带含有显著扩增的局灶区；<span lang="EN-US">KM1</span>亚型的<span lang="EN-US">16p13.3</span>和<span lang="EN-US">KM2</span>亚型的<span lang="EN-US">1p35-36.32</span>、<span lang="EN-US">8p111.22</span>、<span lang="EN-US">18q11.2</span>中的细胞带包含频繁缺失的区域（<strong>图<span lang="EN-US">4E</span></strong>）。<span lang="EN-US">CNA</span>的基因组改变导致<span lang="EN-US">KRAS</span>突变亚型的分子异质性。在<span lang="EN-US">TCGA KRAS</span>突变亚型中也发现了<span lang="EN-US">SCNA</span>细胞带中的类似遗传变异（<strong>图<span lang="EN-US">S5E</span></strong>）。</span></p><p><img data-backh="405" data-backw="578" data-galleryid="" data-ratio="0.6999182338511856" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RxWs7ohJNb4DMS0BNnLkNqHwxjoSTy0NdibNv0JIDAB4Jv71zH9QNjjQ/640?wx_fmt=png" data-type="png" data-w="1223" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RxWs7ohJNb4DMS0BNnLkNqHwxjoSTy0NdibNv0JIDAB4Jv71zH9QNjjQ/640?wx_fmt=png"></p><p><span>图4.<span lang="EN-US">KRAS Mut结直肠癌的肿瘤基因组变异</span></span><br></p><p><img data-backh="138" data-backw="401" data-galleryid="" data-ratio="0.34318398474737843" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RNlZ3zfWich8q53E9ddmBaUec0KWJSVxbks2KT2zZUNyls23B9mpmVrQ/640?wx_fmt=png" data-type="png" data-w="1049" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RNlZ3zfWich8q53E9ddmBaUec0KWJSVxbks2KT2zZUNyls23B9mpmVrQ/640?wx_fmt=png"></p><p><span>图S6D-E.<span>KRAS Mut</span><span>结直肠癌的臂级SCNA</span></span></p><section><span></span></section><section><span></span></section><section><strong><span>5.<strong><span><span>以特定临床特征和分子过程为特征的<span lang="EN-US">KRAS</span>突变模式</span>:</span></strong></span></strong><span lang="EN-US">KRAS</span><span>突变体亚型的前<span lang="EN-US">50</span>个差异表达<span lang="EN-US">mRNA</span>转录物、蛋白质和磷酸蛋白如热图所示（<strong>图<span lang="EN-US">5A</span></strong>）。所有<span lang="EN-US">MSI</span>阳性肿瘤都聚集在<span lang="EN-US">KRAS-WT</span>亚群中，并导致高突变表型、<span lang="EN-US">MSI</span>和免疫相关<span lang="EN-US">CMS1</span>转录组亚型以及<span lang="EN-US">BRAF</span>和<span lang="EN-US">ARID1A</span>突变的聚集。<span lang="EN-US">KM2</span>与晚期肿瘤分期、间充质表型、<span lang="EN-US">CMS4</span>转录组亚型、<span lang="EN-US">ProS-C</span>蛋白质组亚型和免疫亚型<span lang="EN-US">2</span>（<strong>图<span lang="EN-US">5A-B</span></strong>）相关，这表明基质侵袭、血管生成和预后较差。<span lang="EN-US">KM1</span>亚型主要表现为肿瘤早期阶段、<span lang="EN-US">CIN</span>表型、上皮和代谢相关<span lang="EN-US">CMS3</span>转录组亚型、<span lang="EN-US">ProS-E</span>蛋白质组亚型和免疫亚型<span lang="EN-US">1</span>（<strong>图<span lang="EN-US">5A-B</span></strong>），这表明上皮特征和更好的生存结果。<span lang="EN-US">TCGA</span>队列中也发现了类似的结果（<strong>图<span lang="EN-US">5C</span></strong>）。作者进一步分析了肿瘤生物学特征，以探索<span lang="EN-US">KRAS Mut</span>亚群中的代表性免疫和癌症相关过程。在<span lang="EN-US">CPTAC</span>队列中，在前六个差异分子特征中，<span lang="EN-US">KM2</span>亚群表现出巨噬细胞、<span lang="EN-US">MDSCs</span>、缺氧特征、<span lang="EN-US">EMT</span>特征、泛成纤维细胞<span lang="EN-US">TGFb</span>反应<span lang="EN-US">signatrue(Pan-F-TBRS)</span>和基质分数的最高富集，其次是<span lang="EN-US">KM1</span>亚群和<span lang="EN-US">KRAS-WT</span>亚群（<strong>图<span lang="EN-US">5D</span></strong>）。<span lang="EN-US">ImmuneScore</span>和<span lang="EN-US">T</span>细胞耗竭水平在<span lang="EN-US">KRAS</span>亚群中也有差异分布，但突变负荷无统计学意义（<strong>图<span lang="EN-US">S6A</span></strong>）。此外，还在<span lang="EN-US">TCGA</span>队列中进行了相同的分析，并获得了类似的结果（图<span lang="EN-US">S6B-S6C</span>）。进一步采用<span lang="EN-US">xCell</span>算法对三个<span lang="EN-US">KRAS</span>亚群组织中的细胞异质性进行解码。<span lang="EN-US">KM2</span>的特征在于活化的树突状细胞（<span lang="EN-US">aDC</span>）、脂肪细胞、星形胶质细胞、<span lang="EN-US">M2</span>巨噬细胞、间充质干细胞（<span lang="EN-US">MSCs</span>）等的增加，<span lang="EN-US">KM1</span>亚群通过记忆<span lang="EN-US">B</span>细胞和<span lang="EN-US">NK</span>细胞来区分（<strong>图<span lang="EN-US">5E</span></strong>）。</span></section><section><span></span><span></span></section><p><img data-backh="490" data-backw="523" data-galleryid="" data-ratio="0.9366120218579235" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RczO2tsCic0KTWd6369XuacLeYA9q4bhHk5FvHS3NliaficJ6kRgBqyHVg/640?wx_fmt=png" data-type="png" data-w="915" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RczO2tsCic0KTWd6369XuacLeYA9q4bhHk5FvHS3NliaficJ6kRgBqyHVg/640?wx_fmt=png"></p><p><span>图5.以特定临床特征和分子过程为特征的KRAS Mut模式。</span></p><p><strong><span>6.蛋白质组学和磷酸蛋白质组学分析对KRAS突变模式的注释：</span></strong><span>作者基于RNA、蛋白质和磷蛋白水平上对KM1和KM2肿瘤亚群进行了转录后修饰（PTM）和Metascape分析以进一步阐明KRAS突变亚型的生物学意义。RNA和蛋白质水平的途径富集表明，KM1主要富集于过氧化物酶体、MYC靶点和Wntβ-连环蛋白途径，而KM2主要富集于EMT、凝血、血管生成、KRAS信号传导和肌肉生成过程（<strong>图6A</strong>）。磷蛋白数据集的PTM分析表明，KM2的特征在于PKACA、VEGF、PI3K（LY-294002）和JAK（托法替尼）激酶活性的上调，而KM1肿瘤的特征在于MEK（曲美替尼）、PI3K/mTOR（dactolisib）和紫杉醇的药物靶点。此外，EMT过程的代表性蛋白质（COL3A1、VIM、ECM1和LAMC1）和血管生成途径（POSTN、VCAN和ITGAV）在KM2亚型中显著过表达（<strong>图6B</strong>）。而RBM15和HNRNPM（与RNA转录和修饰相关的代表性基因）以及RFC4和CDK11B（与细胞周期和有丝分裂相关的代表基因）在KM1亚型中明显过度表达（<strong>图6B</strong>）。随后，作者基于MCODE算法，鉴定了18个蛋白质亚簇。随后，作者比较了CPTAC队列中KM1和KM2亚组中磷酸化位点的表达，发现在KM2亚群中，粘附信号相关磷酸化和间质表型相关位点磷酸化显著上调。此外，KM1亚组中酪氨酸蛋白激酶受体EPHB2-S776和细胞周期相关蛋白CDK11A-S577和CDK13-S432的水平显著升高（<strong>图6C</strong>）。作者根据差异磷酸化位点进行了途径和过程富集分析。发现，许多通路和功能显著丰富且大多数由KRAS亚型介导（<strong>图6D</strong>）。CPTAC和CCRC队列中的进一步激酶底物富集分析显示，KM1亚群中CDC样激酶CLK1/2、细胞周期蛋白依赖激酶CDK1/7和细胞外信号调节激酶（ERKs）MAPK1/3显著富集；然而，凋亡相关激酶PAK2和PAK5以及AKT丝氨酸-苏氨酸蛋白激酶在KM2亚群中显著富集（<strong>图6E</strong>）。</span></p><p><img data-backh="472" data-backw="522" data-galleryid="" data-ratio="0.9036402569593148" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RQ36UbT1YevhInlCt0qkpdU1sib3Y9bwTEvqwPF3cBeknyclXyBl6MnA/640?wx_fmt=png" data-type="png" data-w="934" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RQ36UbT1YevhInlCt0qkpdU1sib3Y9bwTEvqwPF3cBeknyclXyBl6MnA/640?wx_fmt=png"></p><p><span>图6.磷酸蛋白质组分析对KRAS Mut亚型的功能注释。</span></p><p><strong><span>6.药物敏感性分析揭示KRAS Mut结直肠癌的亚群特异性治疗：</span></strong><span>作</span><span>者在癌症依赖图（</span><span>DepMap</span><span>）数据集中比较了大肠癌细胞系中基于大规模</span><span>RNAi</span><span>筛选的基因依赖性。筛选了</span><span>41</span><span>个</span><span>KRAS</span><span>突变</span><span>CRC</span><span>细胞系，并将其分类为</span><span>KM1</span><span>或</span><span>KM2</span><span>亚群。我们确定了</span><span>KM1</span><span>和</span><span>KM2</span><span>亚群之间具有显著不同依赖性得分（平均依赖性得分差异</span><span>&lt;-0.</span><span>25</span><span>，</span><span> P&lt;0.05</span><span>）的</span><span>31</span><span>个基因（</span><strong><span>图</span><span>7A</span></strong><span>）。使用小于</span><span>-0.3</span><span>的平均依赖性得分作为截止值，我们确定了</span><span>13</span><span>个基因作为亚群特异性癌症依赖性基因（</span><strong><span>图</span><span>7B</span></strong><span>）。其中，</span><span>KM2</span><span>亚型包括</span><span>PI3K/AKT</span><span>信号相关的</span><span>ZFP36L1</span><span>和</span><span>VEGF</span><span>信号相关的</span><span>COL5A1</span><span>和</span><span>TLN1</span><span>；</span><span>KM1</span><span>亚型具有细胞周期</span><span>/</span><span>有丝分裂依赖性</span><span>CCNB3</span><span>、</span><span>RAD21</span><span>和核心</span><span>Wnt</span><span>信号分子</span><span>CTNNB1</span><span>。</span></p><p><img data-backh="866" data-backw="422" data-galleryid="" data-ratio="2.052132701421801" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RIP57MQYgfG1oSBPXT1nLUfIICCdpLmux9wbyQJlnk9cp7picAPq0DKQ/640?wx_fmt=png" data-type="png" data-w="422" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RIP57MQYgfG1oSBPXT1nLUfIICCdpLmux9wbyQJlnk9cp7picAPq0DKQ/640?wx_fmt=png"><span></span></p><p><span>为了进一步鉴定KRAS突变CRC亚型的亚群特异性治疗剂，作者利用了三个药物反应数据库（CTRP-v2、PRISM和GDSC1）来研究KM1和KM2细胞亚群的潜在治疗剂（<strong>图7C</strong>）。进行KM1和KM2亚组之间的差异药物反应分析，以确定各组中AUC估计值较低的特定化合物（调整后P&lt;0.05）。这些分析产生了8种CTRP衍生化合物（KM1为3种，KM2为5种）和10种PRISM衍生化合物（KM 1为7种，KM3为3种）以及11种GDSC衍生化合物（5种，KM1为6种）（<strong>图7C</strong>）。</span></p><p><span><img data-backh="236" data-backw="578" data-galleryid="" data-ratio="0.4086502609992543" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Rkn14JVaJFupibUju169ibAicSMPLCYcQWYpicgwypfaictmr8BCfnZcX0fw/640?wx_fmt=png" data-type="png" data-w="1341" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Rkn14JVaJFupibUju169ibAicSMPLCYcQWYpicgwypfaictmr8BCfnZcX0fw/640?wx_fmt=png"></span></p><p><span><span>随后作者使用连接性图（CMap）数据集来鉴定基因表达模式与KRAS亚型特异性表达模式相反的化合物。</span><span>KM2亚型的六种化合物和KM1亚型的三种化合物的CMap得分低于-90（<strong>图7D</strong>）。</span><span>总的来说，PI3K/AKTi、MEKi和FGFRi在体外和电子证据中都是最有希望的KM2 CRC患者治疗潜力。</span><span>此外，氟哌啶和CDKi在KM1 CRC患者中具有良好的治疗潜力。</span><span>最后作者生成了一个概述KRAS Mut亚型信号通路的示意图，以概述在KRAS突变CRC中的发现（<strong>图7E</strong>）。</span></span></p><p><img data-backh="301" data-backw="578" data-galleryid="" data-ratio="0.5202604920405209" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RWldXmYY6qlA34e0lT4uhtUZ4e4c6hictrOWEjyKOeZETRPEkmEhvLQQ/640?wx_fmt=png" data-type="png" data-w="1382" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RWldXmYY6qlA34e0lT4uhtUZ4e4c6hictrOWEjyKOeZETRPEkmEhvLQQ/640?wx_fmt=png"><br></p><p><img data-backh="367" data-backw="578" data-galleryid="" data-ratio="0.6351902173913043" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Ru8hHZeicbs9h42CyPhoKzD9XQqyo4NCibX6C4Z7my3wWH4QhuiaMpfXWQ/640?wx_fmt=png" data-type="png" data-w="1472" src="https://mmbiz.qpic.cn/mmbiz_png/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0Ru8hHZeicbs9h42CyPhoKzD9XQqyo4NCibX6C4Z7my3wWH4QhuiaMpfXWQ/640?wx_fmt=png"><span></span></p><h3><span>四、总结</span></h3><p><span>1. CRC中KRAS突变的分子机制和临床意义尚不清楚，并在这些肿瘤中表现出高度异质性；信号网络的复杂性和多个KRAS突变等位基因的异质性特征导致难以开发针对KRAS突变肿瘤的分子靶向治疗。</span></p><p><span><br></span></p><p><span><span>2.本文通过整合</span><span>KRAS</span><span>突变</span><span>CRC</span><span>肿瘤的多组学数据（基因组、转录组学、蛋白质组学和磷酸蛋</span><span>白质组学等）特征，揭示了</span><span>KRAS</span><span>突变结直肠癌中靶向信号蛋白、磷酸位点和基因组改变的新分子亚型和治疗策略，促进</span><span>了</span><span>KRAS</span><span>突变</span><span>CRC</span><span>异质性的理解，同时也为开发更有前景的</span><span>KRAS</span><span>靶点提供了方法</span></span></p><p><span>偷</span><span>偷告诉你，我们在B站还有优质文</span><span>章分享视频哦~</span><br></p><p><span></span></p><p><img data-galleryid="" data-ratio="1" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RWImoqneiazU2bw6htGGOianZ8ELDZ8xbuYQP8bAfxPJzepZsYEa2vSTQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="960" src="https://mmbiz.qpic.cn/mmbiz_jpg/eBfvI7Ryx8dJWBtK6GG4AYCVmSd29ia0RWImoqneiazU2bw6htGGOianZ8ELDZ8xbuYQP8bAfxPJzepZsYEa2vSTQ/640?wx_fmt=jpeg"></p><section>写在后面</section><section>医学僧的心愿是为医学僧的支持者和科研爱好者营造一个勤学好问、互帮互助、共同进步的优良环境。但是人多了难免鱼龙混杂，良莠不齐，群里不乏有真心实意、脚踏实地的科研人，我们很尊重并欢迎他们，因此不希望被少数来发广告的、划水的、看热闹的、占个坑的所打扰，最终我们的心意付之东流，大家的热情消磨殆尽。为了解决这个问题，我们决定提高入群的门槛——收费进群，这样，愿意进群的同志相信也是个圈内活跃用户，圈内人相互交流，岂不快哉！</section><section>因此，为了提升大家的效率，调动大家的积极性，吸收真正的科研爱好者，形成一个良好的学习交流氛围，我们决定增加群的数量，并细化群的功能，暂时增加以下几个主题群：</section><ul><li><p>文献下载-医学僧</p></li><li><p>机器学习（分类）-医学僧</p></li><li><p>ggplot可视化-医学僧</p></li><li><p>热图可视化-医学僧</p></li><li><p>TCGA挖掘-医学僧</p></li><li><p>GEO挖掘-医学僧</p></li><li><p>肿瘤预后模型-医学僧</p></li><li><p>肿瘤分子亚型-医学僧</p></li></ul><p>欢迎小伙伴们进群👏👏👏，每个群收费15元。请联系小编微信yixuesengkyrj或扫描下面二维码：</p><p><img data-ratio="0.8407407407407408" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/eBfvI7Ryx8enibib3UJd6iaLibROb1ibWJtZn0fyA9Bu9szdIkibpzWVzjw0LIVrQKeHfPS7h1gI8bicaaYlcOnMIyQAQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_jpg/eBfvI7Ryx8enibib3UJd6iaLibROb1ibWJtZn0fyA9Bu9szdIkibpzWVzjw0LIVrQKeHfPS7h1gI8bicaaYlcOnMIyQAQ/640?wx_fmt=jpeg"></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/WMhRmUWP98MsV2HCUNkhYw",target="_blank" rel="noopener noreferrer">原文链接</a>
